CSI Intelligent Finance Sanxin Medical (300453) disclosed its third quarter report for 2022 on October 20. In the first three quarters of 2022, the company achieved total operating income of 985 million yuan, and increased by 19.13% year-on-year; net profit attributable to shareholders was 143 million yuan, a year-on-year increase of 24.48%; net profit excluding non-operating items was 134 million yuan, a year-on-year increase of 26.71%; net cash flow generated by operating activities was 130 million yuan, a year-on-year decrease of 35.96%; during the reporting period, Sanxin Medical 's basic earnings per share was 0.3617 yuan, and the weighted average return on assets was 17.23%.
According to the third quarter report, the company achieved total operating income of 324 million yuan in the third quarter, a year-on-year increase of 2.17%, and a month-on-month decrease of 4.24%; net profit attributable to shareholders was 37.7908 million yuan, a year-on-year decrease of 12.79% and a month-on-month decrease of 34.04%; net profit excluding non-network was 35.0695 million yuan, a year-on-year decrease of 9.91%, and a month-on-month decrease of 32.20%.
In the first three quarters of 2022, the company's gross profit margin was 34.54%, an increase of 0.27 percentage points year-on-year; the net profit margin was 15.53%, an increase of 0.18 percentage points from the same period last year. Judging from the single-quarter indicators, the company's gross profit margin in the third quarter of 2022 was 31.75%, a year-on-year decrease of 1.85 percentage points and a month-on-month decrease of 4.30 percentage points; the net profit margin was 12.81%, a decrease of 2.20 percentage points from the same period last year and a decrease of 5.19 percentage points from the previous quarter.
In the third quarter of 2022, the company's return on equity was 3.82%, a year-on-year decrease of 1.42 percentage points and a month-on-month decrease of 2.13 percentage points.
In the first three quarters of 2022, the company's operating activities cash flow was RMB 130 million, a year-on-year decrease of 35.96%, mainly due to the increase in inventory balance during the reporting period; the net cash flow of financing activities was RMB 81.0367 million, a year-on-year increase of RMB 196 million, mainly due to the increase in borrowings during the reporting period; the net cash flow of investment activities was RMB -222 million, compared with the same period last year -27.901 million, mainly due to the purchase of financial management and the increase of fixed assets during the reporting period.
In the first three quarters of 2022, the company's operating income cash ratio was 112.24%, and the net cash ratio was 90.96%.
In the first three quarters of 2022, the company's period expenses were 164 million yuan, an increase of 27.7073 million yuan over the same period last year; the period expense ratio was 16.68%, an increase of 0.16 percentage points from the same period last year. Among them, sales expenses decreased by 9.18% year-on-year, administrative expenses increased by 63.53% year-on-year, R&D expenses increased by 29.49% year-on-year, and financial expenses changed from 2.5783 million yuan in the same period last year to -379,700 yuan.
According to the announcement, changes in management expenses are mainly due to the increase in equity incentive expense amortization during the reporting period; changes in financial expenses are mainly due to the increase in interest income and exchange income during the reporting period. In terms of major changes in
assets, as of the end of the third quarter of 2022, the company's fixed assets decreased by 1.48% from the end of the previous year, accounting for 5.47 percentage points of the company's total assets; construction projects increased by 45.98% from the end of the previous year, accounting for 2.66 percentage points of the company's total assets, mainly due to the increase in investment in equipment and workshop construction to be installed during the reporting period; monetary funds increased by 0.91% from the end of the previous year, accounting for 2.44 percentage points of the company's total assets; inventory increased by 34.41% from the end of the previous year, accounting for 1.64 percentage points of the company's total assets, mainly due to the increase in the production of dialyzer during the reporting period, and its corresponding raw materials and inventory goods increased.
In terms of major changes in liabilities, as of the end of the third quarter of 2022, the company's short-term loans increased by 129.63% from the end of the previous year, accounting for 2.55 percentage points, mainly due to the increase in borrowings during the reporting period; accounts payable increased by 13.38% from the end of the previous year, accounting for 0.24 percentage points of the company's total assets; contract liabilities decreased by 22.57% from the end of the previous year, accounting for 1.07 percentage points of the company's total assets; other current liabilities decreased by 72.59% from the end of the previous year, accounting for 0.28 percentage points of the company's total assets. In terms of debt repayment ability, the company's debt-to-asset ratio at the end of the third quarter of 2022 was 33.92%, an increase of 3.53 percentage points from the end of the previous year; the interest-bearing debt-to-asset ratio of was 5.18%, an increase of 2.42 percentage points from the end of the previous year.
The third quarter report shows that among the top ten circulating shareholders of the company at the end of the third quarter of 2022, the new shareholder was Zhao Yangmin, replacing Chen Cheng at the end of the second quarter. In terms of specific shareholding ratios, Xu Guotao's shareholding has increased, while Wu Jinhan and Peng Jiulian's shareholding has decreased.
| Share name | Stock holders (ten thousand shares) | Sales proportion (%) | Total share capital (%) | Changes proportion (%) | |||
|---|---|---|---|---|---|---|---|
| Peng Yixing | 2441.85 | 6.197149 | unchanged | ||||
| 10kls130kls14 | 1234.48 | 3.132984 | unchanged | 310kls130kls14 | 133.132984 | unchanged | 3 |
| Lei Fenglian | 496.55 | 1.260186 | unchanged | ||||
| Peng Haibo | 475.13 | 1.205817 | unchanged | ||||
| Xu Guotao | 281.11 | 0.713427 | 0.00 | 0.00 | |||
| Wang Laidi | 256.31 | 0.650487 | unchanged | ||||
| Zhang Youzhen | 252.12 | 0.639854 | unchanged | ||||
| Wu Jinhan | 228.99 | 0.58114 | -0.00 | ||||
| Peng Jiulian | 216.47 | 0.549369 | -0.04 | ||||
| Zhao Yangmin | 191.77 | 0.486679 | New |
In terms of chip concentration, as of the end of the third quarter of 2022, the total number of shareholders of the company was 21,000, an increase of 1,070 from the end of the second quarter, an increase of 5.36%; the average shareholding market value dropped from 196,300 yuan at the end of the second quarter to 171,300 yuan, a decrease of 12.74%.
